驱动基因阴性晚期非小细胞肺癌一线免疫治疗进展<sup>★</sup>

doi:10.3969/j.issn.2095-1264.2025.05.05

首页 > 过刊浏览>2025年第15卷第5期 >600-608. DOI:10.3969/j.issn.2095-1264.2025.05.05

驱动基因阴性晚期非小细胞肺癌一线免疫治疗进展★
DOI:
                        10.3969/j.issn.2095-1264.2025.05.05
                    
CSTR:
                        
                    
作者:
                        
                        
                    
作者单位:1.石河子大学医学院，新疆 石河子，832003;2.华中科技大学同济医学院附属协和医院肿瘤中心，湖北 武汉，430022;3.肿瘤精准放射治疗湖北省重点实验室，湖北 武汉，430022;4.华中科技大学同济医学院附属协和医院肿瘤放射治疗研究所，湖北 武汉，430022
作者简介:戴韵菲，女，本科生，研究方向为恶性肿瘤化放疗。
通讯作者:黄昱，男，博士，主治医师，研究方向为恶性肿瘤化放疗。
中图分类号:R734.2;R979.5
基金项目:国家自然科学基金青年项目（82103004）；肿瘤精准放射治疗湖北省重点实验室开放基金（2024ZLJZFL001）；华中科技大学同济医学院第一临床学院毕业后教学改革研究项目（XHBJ-2024014）。

Advances in first-line immunotherapy for driver gene-negative advanced non-small cell lung cancer^★

Author:

Affiliation:

1.Shihezi University School of Medicine, Shihezi, 832003, Xinjiang, China;2.Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, Hubei, China;3.Hubei Key Laboratory of Precision Radiation Oncology, Wuhan, 430022, Hubei, China;4.Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, Hubei, China

Fund Project:

摘要

图/表

访问统计

参考文献

相似文献

引证文献

资源附件

文章评论

摘要:

在非小细胞肺癌（NSCLC）的治疗中，以免疫检查点抑制剂（ICI）为代表的免疫治疗药物已显著改善驱动基因阴性晚期患者的临床结局，并展现出良好的治疗效果。对于PD-L1高表达的晚期NSCLC患者，ICI单药已获批用于一线治疗。多项Ⅲ期临床试验证实，ICI单药联合化疗在驱动基因阴性晚期NSCLC一线治疗中可显著改善患者预后。此外，其他联合治疗策略，如ICIs联合抗血管生成药物、免疫双药联合疗法、免疫治疗联合抗体药物偶联物（ADC）等，也显示出可观的疗效和应用潜力。目前，针对不同作用靶点和机制的新型免疫疗法及其联合方案正在多项临床试验中进行评估，这些研究不仅对进一步提升NSCLC患者的临床预后具有重要意义，也持续推动着肺癌免疫治疗领域的研发进展。

Abstract:

Immunotherapeutic agents represented by immune checkpoint inhibitor (ICI) have demonstrated favorable efficacy in non-small cell lung cancer (NSCLC), changing the treatment strategy for driver gene-negative advanced NSCLC. For advanced NSCLC patients with high PD-L1 expression, ICI monotherapy has been approved as a first-line treatment. Multiple phase Ⅲ clinical trials have confirmed that ICI monotherapy combined with chemotherapy significantly improves patient prognosis in the first-line treatment of driver gene-negative advanced NSCLC. Other combination strategies, such as ICI combined with anti-angiogenic therapy, dual immunotherapy, and immunotherapy combined with antibody-drug conjugate, have also shown promising efficacy and application potential. Novel immunotherapeutic agents with different targets and mechanisms, as well as various combination regimens, are currently under investigation in clinical trials. These efforts are not only crucial for further improving the clinical outcomes of NSCLC patients but also continuously propelling advancements in the field of lung cancer immunotherapy research and development.